Shrizine Injection

Shrizine Injection



SM Pharmaceuticals


SM Pharmaceuticals
Concise Prescribing Info
Fluphenazine decanoate
Dosage/Direction for Use
Adult Initially 12.5-25 mg IM/SC repeated or increased every 1-3 wk as needed. Maintenance treatment: 50 mg IM/SC every 1-4 wk as needed, may be increased by 12.5-mg increments. Max: 100 mg/dose.
Hypersensitivity to fluphenazine & other phenothiazines. Preexisting CNS depression or coma, bone-marrow suppression or phaeochromocytoma. Impaired CV, cerebrovascular & resp function. Closed-angle glaucoma, parkinsonism, DM, hypothyroidism, myasthenia gravis or prostatic hypertrophy, subcortical damage. May affect ability to drive or operate machinery. Renal & hepatic impairment.
Special Precautions
Not for short-term therapy. NMS. Epileptic patients. Regular eye exam in long-term therapy. Avoid administration at extreme temp & undue exposure to direct sunlight. Maintain supine position for 30 min & monitor BP after administration. Concomitant use w/ lithium carbonate or antimuscarinic agents; alcohol. Not recommended during pregnancy. Lactation. Not to be used in neonates. Avoid use in childn <2 yr. Elderly & debilitated patients.
Adverse Reactions
Extrapyramidal dysfunction; acute dystonia, parkinsonism-like syndrome, akathisia; dry mouth, constipation, micturition difficulty, blurred vision & mydriasis, hypotension; hypersensitivity reactions eg, urticaria, exfoliative dermatitis, erythema multiforme & contact sensitivity; blood dyscrasias; inj site pain & irritation.
Drug Interactions
Increased CNS depression w/ alcohol, hypnotics, sedatives & strong analgesics. Antagonised action of adrenaline & other sympathomimetic agents. Reversed BP-lowering effects of adrenergic-blocking agents eg, guanethidine & clonidine. Impaired anti-parkinsonian effects of L-dopa, anticonvulsant effects, TCAs metabolism & control of diabetes. Increased effects of anticoagulants. Enhanced anticholinergic effects w/ anti-parkinsonian drugs. Enhanced cardiac-depressant effects of quinidine, absorption of corticosteroid, digoxin & neuromuscular-blocking agents. Severe hypotension w/ ACE inhibitors. Increased plasma conc w/ β-blockers. Inhibited absorption w/ Al- or Mg-containing antacids, adsorbent antidiarrheals. Decreased stimulant effect w/ amphetamines. Intensified anticholinergic side effects of medications w/ anticholinergic action.
MIMS Class
ATC Classification
N05AB02 - fluphenazine ; Belongs to the class of phenothiazine antipsychotics with piperazine structure.
Shrizine inj 25 mg/mL
1 mL x 5 × 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in